Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma

R. Hájek, J. Minařík, J. Straub, L. Pour, A. Jungova, JG. Berdeja, M. Boccadoro, L. Brozova, A. Spencer, F. van Rhee, J. Vela-Ojeda, MA. Thompson, R. Abonour, A. Chari, G. Cook, CL. Costello, FE. Davies, VT. Hungria, HC. Lee, X. Leleu, N. Puig,...

. 2021 ; 17 (19) : 2499-2512. [pub] 20210326

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004136

Grantová podpora
Millennium Pharmaceuticals, Inc., Cambridge, MA, United States, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov).

Advocate Aurora Research Institute Advocate Aurora Health Milwaukee WI 53227 USA

Alfred Health Monash University Melbourne 3004 Australia

Barbara Ann Karmanos Cancer Institute Wayne State University School of Medicine Detroit MI 48201 USA

Charles University Hospital and Faculty of Medicine Hradec Králové 121 08 Czech Republic

Clinica São Germano and Santa Casa Medical School São Paulo 04537 081 Brazil

Department of Hematology Hospital Universitario de Salamanca Salamanca 37007 Spain

Faculty Hospital Pilsen Pilsen 301 00 Czech Republic

General Teaching Hospital Prague 128 08 Czech Republic

Hospital Pablo Tobón Uribe Medellin 11001 Colombia

Icahn School of Medicine at Mount Sinai New York NY 10029 USA

Indiana University School of Medicine Indianapolis IN 46202 USA

Institute of Biostatistics and Analyses Ltd Brno 602 00 Czech Republic

Leeds Teaching Hospital Leeds LS1 3EX UK

Levine Cancer Institute Charlotte NC 115 27 USA

M D Anderson Cancer Center Houston TX 77030 USA

Millennium Pharmaceuticals Inc Cambridge MA 02139 USA a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Moores Cancer Center University of California San Diego La Jolla CA 92037 USA

National and Kapodistrian University of Athens School of Medicine Athens 115 27 Greece

Palacky University and University Hospital Olomouc Olomouc 771 47 Czech Republic

Peking University People's Hospital National Clinical Research Center for Hematologic Disease Beijing 100044 China

Perlmutter Cancer Center NYU Langone New York NY 10016 USA

Pôle Régional de Cancérologie CHU de Poitiers Poitiers 86000 France

Rocky Mountain Cancer Centers US Oncology Research Denver CO 80218 USA

Sarah Cannon Research Institute Nashville TN 37203 USA

UMAE Especialidades Centro Medico La Raza IMSS Ciudad de México 02990 Mexico

University Hospital Brno 625 00 Czech Republic

University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava 703 00 Czech Republic

University Medical Center Hamburg Eppendorf Hamburg 20251 Germany

University of Arkansas for Medical Sciences Little Rock AR 72205 USA

University of Torino Torino 10124 Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004136
003      
CZ-PrNML
005      
20220127145501.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/fon-2020-1225 $2 doi
035    __
$a (PubMed)33769076
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hájek, Roman $u University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, 703 00, Czech Republic
245    10
$a Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma / $c R. Hájek, J. Minařík, J. Straub, L. Pour, A. Jungova, JG. Berdeja, M. Boccadoro, L. Brozova, A. Spencer, F. van Rhee, J. Vela-Ojeda, MA. Thompson, R. Abonour, A. Chari, G. Cook, CL. Costello, FE. Davies, VT. Hungria, HC. Lee, X. Leleu, N. Puig, RM. Rifkin, E. Terpos, SZ. Usmani, KC. Weisel, JA. Zonder, M. Bařinová, M. Kuhn, J. Šilar, L. Čápková, K. Galvez, J. Lu, J. Elliott, DM. Stull, K. Ren, V. Maisnar
520    9_
$a Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov).
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a sloučeniny boru $x aplikace a dávkování $x škodlivé účinky $7 D001896
650    _2
$a dexamethason $x aplikace a dávkování $x škodlivé účinky $7 D003907
650    _2
$a chemorezistence $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glycin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D005998
650    _2
$a lidé $7 D006801
650    _2
$a lenalidomid $x aplikace a dávkování $x škodlivé účinky $7 D000077269
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $x mortalita $x patologie $7 D009101
650    _2
$a lokální recidiva nádoru $x farmakoterapie $x mortalita $7 D009364
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Minařík, Jiří $u Palacky University & University Hospital Olomouc, Olomouc, 771 47, Czech Republic
700    1_
$a Straub, Jan $u General Teaching Hospital, Prague, 128 08, Czech Republic
700    1_
$a Pour, Luděk $u University Hospital, Brno, 625 00, Czech Republic
700    1_
$a Jungova, Alexandra $u Faculty Hospital Pilsen, Pilsen, 301 00, Czech Republic
700    1_
$a Berdeja, Jesus G $u Sarah Cannon Research Institute, Nashville, TN 37203, USA
700    1_
$a Boccadoro, Mario $u University of Torino, Torino, 10124, Italy
700    1_
$a Brozova, Lucie $u Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic
700    1_
$a Spencer, Andrew $u Alfred Health-Monash University, Melbourne, 3004, Australia
700    1_
$a van Rhee, Frits $u University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
700    1_
$a Vela-Ojeda, Jorge $u UMAE Especialidades Centro Medico La Raza IMSS, Ciudad de México, 02990, Mexico
700    1_
$a Thompson, Michael A $u Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI 53227, USA
700    1_
$a Abonour, Rafat $u Indiana University School of Medicine, Indianapolis, IN 46202, USA
700    1_
$a Chari, Ajai $u Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
700    1_
$a Cook, Gordon $u Leeds Teaching Hospital, Leeds, LS1 3EX, UK
700    1_
$a Costello, Caitlin L $u Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA
700    1_
$a Davies, Faith E $u Perlmutter Cancer Center, NYU Langone, New York, NY 10016, USA
700    1_
$a Hungria, Vania Tm $u Clinica São Germano & Santa Casa Medical School, São Paulo, 04537-081, Brazil
700    1_
$a Lee, Hans C $u M.D. Anderson Cancer Center, Houston, TX 77030, USA
700    1_
$a Leleu, Xavier $u Pôle Régional de Cancérologie, CHU de Poitiers, Poitiers, 86000, France
700    1_
$a Puig, Noemi $u Department of Hematology, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC (CB16/12/00233), Salamanca, 37007, Spain
700    1_
$a Rifkin, Robert M $u Rocky Mountain Cancer Centers US Oncology Research, Denver, CO 80218, USA
700    1_
$a Terpos, Evangelos $u National & Kapodistrian University of Athens, School of Medicine, Athens, 115 27, Greece
700    1_
$a Usmani, Saad Z $u Levine Cancer Institute, Charlotte, NC 115 27, USA
700    1_
$a Weisel, Katja C $u University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany
700    1_
$a Zonder, Jeffrey A $u Barbara Ann Karmanos Cancer Institute / Wayne State University School of Medicine, Detroit, MI 48201, USA
700    1_
$a Bařinová, Magda $u Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic
700    1_
$a Kuhn, Matyáš $u Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic
700    1_
$a Šilar, Jiří $u Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic
700    1_
$a Čápková, Lenka $u Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic
700    1_
$a Galvez, Kenny $u Hospital Pablo Tobón Uribe, Medellin, 11001, Colombia
700    1_
$a Lu, Jin $u Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Beijing, 100044, China
700    1_
$a Elliott, Jennifer $u Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
700    1_
$a Stull, Dawn Marie $u Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
700    1_
$a Ren, Kaili $u Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
700    1_
$a Maisnar, Vladimír $u Charles University Hospital & Faculty of Medicine, Hradec Králové, 121 08, Czech Republic
773    0_
$w MED00008687 $t Future oncology (London, England) $x 1744-8301 $g Roč. 17, č. 19 (2021), s. 2499-2512
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33769076 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145457 $b ABA008
999    __
$a ok $b bmc $g 1751566 $s 1155285
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 17 $c 19 $d 2499-2512 $e 20210326 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
GRA    __
$p Millennium Pharmaceuticals, Inc., Cambridge, MA, United States, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace